SCHEMBL6844857

SCHEMBL6844857

O=C(O)c1cc(Br)ccc1CBr

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
GLA P06280 1/20 0.55
APEX1 P27695 1/20 0.47
MYC P01106 1/20 0.46
NR4A1 P22736 1/20 0.46
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GPR35 Q9HC97 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
HPGD P15428 2/20 0.44
CES2 O00748 1/20 0.44
GALR3 O60755 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1500169 0.84 KDM4E (0.50) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL11380046 0.84 HPGD (0.44) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL31125276 0.84 KDM4E (0.55) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL3172005 0.84 KDM4E (0.55) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL23243427 0.84 KDM4E (0.55) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL1400054 0.82 KDM4E (0.53) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL31529596 0.82 KDM4E (0.58) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL12896001 0.82 PTGDR2 (0.50) KDM4EGLAMYCNR4A1HPGD
SCHEMBL31053264 0.82 KDM4E (0.53) KDM4EGLAAPEX1MYCNR4A1
SCHEMBL25612072 0.82 KDM4E (0.58) KDM4EGLAAPEX1MYCNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
US-5395610-A Agents for potentiating the effects of antitumor agents and combating multiple drug resistance BURROUGHS-WELLCOME CO. (US) 1995-03-07 US disclosed